Dr Eva Ehrnrooth, MD PhD to join One-carbon Therapeutics AB management team as interim CMO
Dr Eva Ehrnrooth (MD PhD) brings + 20 years of experience in Clinical Development focused on Oncology. Her expertise spans, small molecules, monoclonal antibodies and vaccines. She led global clinical development across various solid tumor indications at Boehringer-Ingelheim, Genmab and Novo Nordisk. She has a proven track record of building and leading development teams, successful […]
One-carbon therapeutics AB management at ESMO to discuss the ODIN clinical phase 1/2 trial with potential clinical sites across Europe
One-carbon therapeutics AB is discussing the ODIN trial with several leading clinical sites at the upcoming ESMO meeting in Barcelona. The ODIN trial is a first-in-human, first-in-class clinical phase 1/2 trial with MTHFD1/2 inhibitor TH9619 in selected solid cancers.
Our Founder Prof Thomas Helleday wins the Anders Jahre’s price in Medicine
Read the article here.
One-carbon therapeutics AB is moving into new offices
In preparation and expansion for the upcoming clinical trial, we have moved into a new office to house the clinical development staff.
One-carbon Therapeutics receives US patent
We are happy to announce that on the 22nd of November 2022 One-carbon Therapeutics received confirmation from the US patent office that a key patent covering the company’s leading drug candidate for the treatment of cancers, inflammation, autoimmune diseases has been granted. The granting of this patent establishes our strong IP portfolio and lays the […]
We are presenting at Bio-Europe 2022, October 24–26, Leipzig, Germany
We look forward to meeting you in person and sharing updates on our progress in bringing innovative medicine to the clinic and providing new options for cancer patients.
One-carbon therapeutics wins ELAVITY Pitch Event
Our team is happy and proud to have been voted as the winner for pitching our MTHFD1/2 inhibitor program. https://www.linkedin.com/feed/update/urn:li:activity:6948268990171365376
Pitch prize in Bordeaux
The MTHFD2 program is pitched by CEO Dr Ana Slipicevic at the Meet2Win conference in Bordeaux and wins a pitch price!
Vinnova grants one-carbon therapeutics money
One-carbon therapeutics AB is granted 3,000,000 SEK from Sweden’s innovation agency Vinnova under the Medtech4Health and SweLife programs for further development of the MTHFD2 program.
One-carbon therapeutics AB recieves SME status by EMA
One-carbon therapeutics AB receives SME status by EMA The incentives offered by the SME Regulation give access to: Regulatory assistance: SMEs can benefit from direct regulatory assistance including SME briefing meetings, to provide guidance on the EU regulatory framework and the tools to support innovation. Scientific advice: A substantial fee reduction for scientific advice is available […]